Literature DB >> 32470501

Central Airway Toxicity After High Dose Radiation: A Combined Analysis of Prospective Clinical Trials for Non-Small Cell Lung Cancer.

Weili Wang1, Martha M Matuszak2, Chen Hu3, Ke Colin Huang4, Eileen Chen1, Douglas Arenberg5, Jeffrey L Curtis6, Shruti Jolly2, Jian-Yue Jin1, Mitchell Machtay1, Randall K Ten Haken2, Feng-Ming Spring Kong7.   

Abstract

PURPOSE: To study the dosimetric risk factors for radiation-induced proximal bronchial tree (PBT) toxicity in patients treated with radiation therapy for non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: Patients with medically inoperable or unresectable NSCLC treated with conventionally fractionated 3-dimensional conformal radiation therapy (3DCRT) in prospective clinical trials were eligible for this study. Proximal bronchial tree (PBT) and PBT wall were contoured consistently per RTOG 1106 OAR-Atlas. The dose-volume histograms (DVHs) of physical prescription dose (DVHp) and biological effective dose (α/β = 2.5; DVH2.5) were generated, respectively. The primary endpoint was PBT toxicities, defined by CTCAE 4.0 under the terminology of bronchial stricture/atelectasis.
RESULTS: Of 100 patients enrolled, with a median follow-up of 64 months (95% confidence interval [CI], 50-78), 73% received 70 Gy or greater and 17% developed PBT toxicity (grade 1, 8%; grade 2, 6%; grade 3, 0%; and grade 4, 3%). The median time interval between RT initiation and onset of PBT toxicity was 8.4 months (95% CI, 4.7-44.1). The combined DVHs showed that no patient with a PBT maximum physical dose <65 Gy developed any PBT toxicity. Cox proportional hazards analysis and receiver operating characteristic analysis demonstrated that V75 of PBT was the most significant dosimetric parameter for both grade 1+ (P = .035) and grade 2+ (P = .037) PBT toxicities. The dosimetric thresholds for V75 of PBT were 6.8% and 11.9% for grade 1+ and grade 2+ PBT toxicity, respectively.
CONCLUSIONS: V75 of PBT appeared be the most significant dosimetric parameter for PBT toxicity after conventionally fractionated thoracic 3DCRT. Constraining V75 of PBT can limit clinically significant PBT toxicity.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2020        PMID: 32470501      PMCID: PMC8074530          DOI: 10.1016/j.ijrobp.2020.05.026

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  17 in total

Review 1.  Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach.

Authors:  S Tyldesley; C Boyd; K Schulze; H Walker; W J Mackillop
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-03-15       Impact factor: 7.038

2.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

3.  Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer?

Authors:  Keith L Miller; Timothy D Shafman; Mitchell S Anscher; Su-Min Zhou; Robert W Clough; Jennifer L Garst; Jeffrey Crawford; Julian Rosenman; Mark A Socinski; William Blackstock; Gregory S Sibley; Lawrence B Marks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-01-01       Impact factor: 7.038

4.  Retrospective cohort study of bronchial doses and radiation-induced atelectasis after stereotactic body radiation therapy of lung tumors located close to the bronchial tree.

Authors:  Kristin Karlsson; Jan Nyman; Pia Baumann; Peter Wersäll; Ninni Drugge; Giovanna Gagliardi; Karl-Axel Johansson; Jan-Olov Persson; Eva Rutkowska; Owe Tullgren; Ingmar Lax
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-11-01       Impact factor: 7.038

5.  Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial.

Authors:  Robert D Timmerman; Rebecca Paulus; Harvey I Pass; Elizabeth M Gore; Martin J Edelman; James Galvin; William L Straube; Lucien A Nedzi; Ronald C McGarry; Cliff G Robinson; Peter B Schiff; Garrick Chang; Billy W Loo; Jeffrey D Bradley; Hak Choy
Journal:  JAMA Oncol       Date:  2018-09-01       Impact factor: 31.777

6.  Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer.

Authors:  Carrie B Lee; Thomas E Stinchcombe; Dominic T Moore; David E Morris; D Neil Hayes; Jan Halle; Julian G Rosenman; M Patricia Rivera; Mark A Socinski
Journal:  J Thorac Oncol       Date:  2009-01       Impact factor: 15.609

7.  PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Suresh Senan; Anthony Brade; Lu-Hua Wang; Johan Vansteenkiste; Shaker Dakhil; Bonne Biesma; Maite Martinez Aguillo; Joachim Aerts; Ramaswamy Govindan; Belén Rubio-Viqueira; Conrad Lewanski; David Gandara; Hak Choy; Tony Mok; Anwar Hossain; Neill Iscoe; Joseph Treat; Andrew Koustenis; Bélen San Antonio; Nadia Chouaki; Everett Vokes
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

8.  A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927).

Authors:  Gregory M M Videtic; Chen Hu; Anurag K Singh; Joe Y Chang; William Parker; Kenneth R Olivier; Steven E Schild; Ritsuko Komaki; James J Urbanic; Robert D Timmerman; Hak Choy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-07-17       Impact factor: 7.038

9.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

10.  Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial.

Authors:  Feng-Ming Kong; Randall K Ten Haken; Matthew Schipper; Kirk A Frey; James Hayman; Milton Gross; Nithya Ramnath; Khaled A Hassan; Martha Matuszak; Timothy Ritter; Nan Bi; Weili Wang; Mark Orringer; Kemp B Cease; Theodore S Lawrence; Gregory P Kalemkerian
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777

View more
  4 in total

1.  Radiation-induced airway changes and downstream ventilation decline in a swine model.

Authors:  Eric M Wallat; Antonia E Wuschner; Mattison J Flakus; Gary E Christensen; Joseph M Reinhardt; Dhanansayan Shanmuganayagam; John E Bayouth
Journal:  Biomed Phys Eng Express       Date:  2021-10-29

2.  Using oxygen dose histograms to quantify voxelised ultra-high dose rate (FLASH) effects in multiple radiation modalities.

Authors:  Frank Van den Heuvel; Anna Vella; Francesca Fiorini; Mark Brooke; Mark Hill; Anderson Ryan; Tim Maughan; Amato Giaccia
Journal:  Phys Med Biol       Date:  2022-06-08       Impact factor: 4.174

3.  Locally advanced NSCLC: a plea for sparing the ipsilateral normal lung-prospective, clinical trial with DART-bid (dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily) by VMAT.

Authors:  Karl Wurstbauer; Margit Kazil; Marco Meinschad; Raoul Pinter; Catharina De Vries; Patrick Clemens; Christof Kreuter; Tamara Hernler; Wolfgang Hitzl; Peter Cerkl; Thomas Künzler; Alexander De Vries
Journal:  Radiat Oncol       Date:  2022-07-07       Impact factor: 4.309

Review 4.  Value of carbon-ion radiotherapy for early stage non-small cell lung cancer.

Authors:  Hanguang Ruan; Juan Xiong
Journal:  Clin Transl Radiat Oncol       Date:  2022-06-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.